Alan Korman
PhD
Vice President, Immuno-Oncology Discovery
👥Biography 个人简介
Dr. Alan Korman is a pioneer in checkpoint antibody development who led anti-CTLA-4 ipilimumab research at BMS, helping translate Jim Allison's discovery into clinical therapy. He has contributed to understanding how the Fc region and isotype of checkpoint antibodies influence mechanism of action, including Treg depletion in tumors versus systemic toxicity. His continued work on engineering next-generation checkpoint antibodies with optimized Fc effector functions informs the pipeline of novel immuno-oncology therapeutics.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Alan Korman 的研究动态
Follow Alan Korman's research updates
留下邮箱，当我们发布与 Alan Korman（Bristol Myers Squibb）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment